Roche : Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy

Investor Update Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy

Dear Investor,

Please find attached a press release from our partner Sarepta Therapeutics:
https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-reports-sustained-functional-improvement

Do not hesitate to contact us for any further questions.

With best regards,

Roche Investor Relations
Dr. Karl Mahler Phone: [phone] e-mail: [e-mail]	Jon Kaspar Bayard Phone: [phone] e-mail: [e-mail]
Dr. Sabine Borngräber Phone: [phone] e-mail: [e-mail]	Dr. Bruno Eschli Phone: [phone] e-mail: [e-mail]
Dr. Birgit Masjost Phone: [phone] e-mail: [e-mail]	Dr. Gerard Tobin Phone: [phone] e-mail: [e-mail]
Investor Relations North America
Loren Kalm Phone: [phone] e-mail: [e-mail]	Dr. Lisa Tuomi Phone: [phone] e-mail: [e-mail]